Analysts at Jefferies have suggested the first-in-class ATP citrate lyase (ACL) inhibitor could achieve peak sales in the region of $2-$3 billion, again depending on a cardiovascular outcomes ...

After hours: 14 February at 19:40:27 GMT-5 ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo ...

Future Rheumatol. 2008;3(1):21-35.

Many or all of the products on this page are from partners who compensate us when you click to or take an action on their website, but this does not influence our evaluations or ratings. Our ...